LONDON, England, Jan. 28 [Category: BizPharmaceuticals] -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP

* If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing

* Submissions based on data from positive SWIFT and ANCHOR trials
. . .

Click here for more information about our products